Latest Ratios: P/E Ratio -1.4x · EV/EBITDA N/A · ROE -54.7%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $13M | $29M | $12M | $7M | $15M | — | — | — | — | — |
| Enterprise Value | $8M | $15M | $30M | $12M | $8M | $5M | — | — | — | — | — |
| P/E Ratio → | -1.37 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.42 | 1.11 | 3.34 | 2.95 | 3.40 | 9.38 | — | — | — | — | — |
| P/B Ratio | 0.84 | 2.59 | 4.78 | 2.34 | 0.91 | 1.20 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.35 | 3.46 | 2.98 | 3.88 | 3.52 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.5% | 39.5% | 31.6% | 9.1% | 12.5% | 0.5% | -43.2% | -19.1% | 23.2% | 7.4% | -5.3% |
| Operating Margin | -29.3% | -29.3% | -40.9% | -85.0% | -163.5% | -165.7% | -335.3% | -268.3% | -85.3% | -48.6% | -86.6% |
| Net Profit Margin | -26.3% | -26.3% | -37.8% | -77.2% | -231.7% | -277.9% | -335.9% | -268.2% | -85.3% | -47.8% | -82.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.7% | -54.7% | -58.3% | -49.3% | -48.1% | -70.9% | -1004.0% | -581.8% | -416.8% | -134.3% | -223.7% |
| ROA | -28.0% | -28.0% | -31.3% | -31.1% | -34.7% | -44.8% | -109.2% | -146.3% | -231.2% | -88.4% | -140.8% |
| ROIC | -34.1% | -34.1% | -43.1% | -37.6% | -43.2% | -89.3% | -144.1% | -219.1% | -312.6% | -102.4% | -176.1% |
| ROCE | -41.9% | -41.9% | -44.7% | -41.1% | -28.4% | -34.2% | -224.3% | -270.6% | -371.7% | -124.2% | -212.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.63 | 0.63 | 0.46 | 0.54 | 0.27 | 0.35 | 17.99 | 2.41 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.57 | 0.17 | 0.02 | 0.13 | -0.75 | 17.54 | 1.73 | 0.00 | 0.00 | 0.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -98.59 | -98.59 | -41.75 | -211.53 | -2.55 | -1.16 | -225.40 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 2.07 | 1.98 | 8.74 | 4.82 | 0.27 | 0.64 | 0.89 | 0.95 | 0.67 |
| Quick Ratio | 0.75 | 0.75 | 1.36 | 1.46 | 8.15 | 4.72 | 0.10 | 0.50 | 0.64 | 0.50 | 0.26 |
| Cash Ratio | 0.11 | 0.11 | 0.73 | 1.06 | 7.69 | 4.62 | 0.02 | 0.33 | — | — | — |
| Asset Turnover | — | 1.09 | 0.79 | 0.41 | 0.20 | 0.09 | 0.30 | 0.38 | 2.99 | 2.23 | 1.71 |
| Inventory Turnover | 3.27 | 3.27 | 3.39 | 2.82 | 3.57 | 5.30 | 4.14 | 7.56 | 16.82 | 19.84 | 14.34 |
| Days Sales Outstanding | — | 21.51 | 39.20 | 56.50 | 39.57 | 49.18 | 39.53 | 51.92 | 5.61 | 18.14 | 12.55 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $8M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M |
Imminent liquidity and dilution
According to current market data, NEXGEL trades at a price-to-sales multiple of 0.42, which appears to reflect significant investor skepticism regarding the company's ability to achieve profitability given its negative TTM P/E of -1.37 and the absence of a clear path to positive earnings.
The low P/S ratio suggests the market is pricing the firm as a distressed asset rather than a high-growth medical technology platform. Investors should monitor whether this valuation gap persists as the company attempts to scale its branded product portfolio, as current multiples imply that the market is heavily discounting the potential for future margin expansion.
Based on reported financial statements, NEXGEL's ROIC has remained consistently negative over the last ten quarters, bottoming out at -17.2% in 2023Q4 and showing little evidence of improvement, which indicates that the company is currently destroying rather than compounding invested capital.
The persistent negative return on capital is a direct consequence of the company's inability to generate sufficient operating income to cover the depreciation of its capital-intensive E-beam infrastructure. This trend warrants further investigation into whether the current manufacturing footprint is oversized for the company's current revenue scale.
As reported in recent filings, NEXGEL's cash conversion cycle remains volatile, reaching 76 days in 2026Q1, which suggests that the company struggles to manage its inventory and receivables effectively compared to the more streamlined operations of its medical device peers.
The high days inventory outstanding, which peaked at 124 days in 2026Q1, indicates a potential buildup of slow-moving consumer products that may require future write-downs. This inefficiency ties up critical cash that the company cannot afford to lose given its precarious liquidity position.
Based on the 2026Q1 balance sheet, the company's current ratio of 1.70 masks a dire cash position of only $317,000, which appears insufficient to support ongoing operations without immediate access to external capital or a significant improvement in cash flow generation.
The quick ratio of 1.02 indicates that the company is heavily reliant on inventory liquidation to meet its short-term obligations, a risky strategy in a sector where product demand can be unpredictable. Investors should monitor the company's ability to secure non-dilutive financing, as the current liquidity profile appears highly vulnerable to operational shocks.
Analysts frequently overemphasize top-line revenue growth as a primary indicator of success for NEXGEL, yet this metric obscures the underlying cash burn and negative operating margins that define the company's current financial reality, according to an analysis of recent quarterly performance trends.
Focusing on revenue growth in a capital-intensive, loss-making business model can be misleading because it ignores the cost of customer acquisition and the fixed-cost burden of the E-beam facility. A more appropriate metric for this business would be the 'burn-adjusted revenue growth' or 'contribution margin per unit,' which would better reflect the sustainability of the company's transition to branded products.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NXGL stock.
NEXGEL, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
NEXGEL, Inc.'s return on equity (ROE) is -54.7%. The historical average is -132.0%.
Based on historical data, NEXGEL, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
NEXGEL, Inc. has 39.5% gross margin and -29.3% operating margin.